Role of Chlorophytum Borivilianum extract against Doxorubicin- induced Myocardial Toxicity in Albino Rats: Insilico and Invivo studies

The doxorubicin, an anthracycline derivative, is a cytotoxic agent with proven efficacy in various malignancies. The clinical utility has been limited due to its dose -dependent cardiac toxicity. To evaluate the role of Chlorophytum borivilianum L. on doxorubicin-induced cardiotoxicity in rats and to predict the role of Chlorophytum borivilianum L. by insilico and in vivo methods. Invitro studies were conducted on Chlorophytum borivilianum L. Cardiotoxicity was produced by administration of doxorubicin (Dox-15 mg/kg ip. for two weeks). Ethanolic extract and fractions of Chlorophytum borivilianum L. (250 and 500 mg/kg, p.o.) were administered as pretreatment for 15 days followed by Doxorubicin 2.5 mg/kg i.p. on alternate day for two weeks. The parameters like body weight, food and water consumption, cardiac specific markers like Creatine Kinase (CK-MB), Lactate Dehydrogenase (LDH) and Cardiac Troponin-I (cTnl), ECG changes, antioxidant parameters like superoxide dismutase (SOD), glutathione (GSH), catalase (CAT) and lipid peroxidation (MDA) were monitored. Histopathological studies of the heart were also performed to evaluate myocardial toxicity. Dox treatment results in cardiomyopathy characterised by elevated cardiac biomarkers and deficiency of antioxidant enzymes. By reducing the elevated levels of biomarker enzymes like LDH and CK-MB and the absence of cTnI, pretreatment with the EECB (500mg/kg) significantly protected the myocardium from the toxic effects of Dox. In addition, the EECB increased the reduced levels of GSH, SOD, and CAT while decreasing the elevated levels of malondialdehyde (MDA) in cardiac tissue.